KejÃk, Z.; Kaplánek, R.; Dytrych, P.; MasaÅ™Ãk, M.; Veselá, K.; Abramenko, N.; Hoskovec, D.; Vašáková, M.; Králová, J.; Martásek, P.;
et al. Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design. Pharmaceutics 2021, 13, 1879.
https://doi.org/10.3390/pharmaceutics13111879
AMA Style
KejÃk Z, Kaplánek R, Dytrych P, MasaÅ™Ãk M, Veselá K, Abramenko N, Hoskovec D, Vašáková M, Králová J, Martásek P,
et al. Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design. Pharmaceutics. 2021; 13(11):1879.
https://doi.org/10.3390/pharmaceutics13111879
Chicago/Turabian Style
KejÃk, ZdenÄ›k, Robert Kaplánek, Petr Dytrych, Michal MasaÅ™Ãk, KateÅ™ina Veselá, Nikita Abramenko, David Hoskovec, Martina Vašáková, Jarmila Králová, Pavel Martásek,
and et al. 2021. "Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design" Pharmaceutics 13, no. 11: 1879.
https://doi.org/10.3390/pharmaceutics13111879
APA Style
KejÃk, Z., Kaplánek, R., Dytrych, P., MasaÅ™Ãk, M., Veselá, K., Abramenko, N., Hoskovec, D., Vašáková, M., Králová, J., Martásek, P., & Jakubek, M.
(2021). Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design. Pharmaceutics, 13(11), 1879.
https://doi.org/10.3390/pharmaceutics13111879